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Glucocorticoids arising from chronic stress and long‑term inflammatory treatment with corticosteroids are both associated with 
neuropathology and cognitive impairments. Many previous studies have focused on changes in brain morphology and deficits in 
learning behavior. However, effects of long‑term exposure to stress hormones on electrical brain signaling and sleep‑wake patterns 
have remained largely unexplored. This study aimed to monitor electroencephalographic (EEG) patterns induced by prolonged 
dexamethasone exposure. Adult male Wistar rats implanted with electrodes on the skull over the frontal and parietal cortices 
were intraperitoneally injected with either saline or dexamethasone (0.5 mg/kg) once daily for 21 consecutive days. Longitudinal 
EEG recording was performed on day 6, 11, 16 and 21. Fast Fourier transform was used for frequency power analysis. One‑way 
ANOVA revealed significant increases in parietal EEG power of slow frequencies (delta, theta and alpha) particularly, with the 
dominant theta activity seen as early as day 11 of dexamethasone treatment. Sleep‑wake analysis on day 21 confirmed a significant 
reduction of rapid‑eye movement (REM) sleep and increased slow frequency oscillations mainly in the parietal cortex during the 
awake period. The number of high‑voltage spindles (HVSs) (6‑10  Hz EEG oscillation) was significantly increased during awake 
and slow wave sleep (SWS) periods following dexamethasone treatment. These findings demonstrated that distinct frequency 
oscillations, sleep‑wakefulness and sleep spindles may be parameters of neuropathology produced by long‑term dexamethasone 
exposure. Early detection of these parameters might be predictive of neuropathology in long‑term corticosteroid users.
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INTRODUCTION
Previously, mental and cognitive deficits known as 
steroid psychosis were found in cases of long‑term an‑
ti‑inflammatory drug treatment (Clark et al., 1952). In 
addition, daily life stress also increased corticosterone 
levels and induced hypothalamic–pituitary–adrenal 
(HPA) axis hyperactivity, anxiety‑like behavior, impair‑
ments in learning and memory, dysfunction in balance 
and motor coordination and volume reductions in mul‑
tiple brain areas, including rodent hippocampus (Jafari 
et al., 2018). Stress hormones produce neurobiological 
effects through glucocorticoid receptors generally lo‑
calized in the brain. In humans, sympathoadrenal sys‑
tem hyperactivity is associated with impaired sleep 
continuity (Hubain et al., 1998). Different brain mech‑
anisms are implicated in sleep disturbances experi‑
enced by people with different mental disorders (Stan‑
er et al., 2003). Many reports have consistently shown 
that stress hormones can cause impairments in sever‑
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al cognitive functions in humans (Lupien et al., 1995; 
2005). These findings suggested an association between 
long‑term exposure and some adverse consequences of 
stress hormones.
It is important to monitor brain activity in a lon‑
gitudinal study to detect possible neuropathological 
evidence as early as possible. Most neurodegenera‑
tive diseases have been diagnosed at late stages when 
pathological symptoms emerge. Many failed treatment 
trials for neurodegenerative diseases have been report‑
ed (Selkoe, 2011; Toyn, 2015). Treatment effectiveness 
appeared to be minimal in the late stage of the diseas‑
es, especially following the emergence of clinical symp‑
toms (Laske, 2014). Effective disease‑modifying ther‑
apies would likely be administered if a diagnosis was 
made at the earliest stage of brain pathology. It is pos‑
sible for researchers to detect abnormal cerebrospinal 
fluid composition in people who do not yet have clin‑
ical symptoms but are at risk for Alzheimer’s disease 
(Fagan et al., 2007). A similar potential application has 
been reported in studies of Parkinson’s disease using 
PET scans (Garraux et al., 2013). Moreover, myelin basic 
protein in cerebrospinal fluid was also found to be a re‑
liable indicator of myelin damage in multiple sclerosis 
(Sellebjerg et al., 1998). These reports hint at the possi‑
bility of early detection for neurodegenerative diseases 
with promising methods. However, these sophisticated 
techniques have been applied mostly at specialized re‑
search centers for neurodegenerative diseases. These 
findings have not had significant impact on neurode‑
generative intervention for the mass population due to 
sparse availability of the techniques.
Subsequently, other non‑invasive and non‑expen‑
sive techniques have been researched. Among the var‑
ious approaches, electroencephalography (EEG) has 
ained enormous attention. Originally, it was primarily 
used for epilepsy research and treatment (Minasyan et 
al., 2010). However, it has also been recognized as a use‑
ful tool for purposes including diagnosis of depression 
(Itil, 1983), attention deficit hyperactivity disorder 
(Snyder and Hall, 2006) and schizophrenia (Kwon et al., 
1999; Uhlhaas et al., 2008). These reports have demon‑
strated that electrical brain signals are rich sources for 
assessing differential brain functions found in various 
conditions or diseases. 
This study aimed to mimic neuropathology induced 
by prolonged dexamethasone therapy in a rat model. 
Therefore, EEG signals were recorded for frequency 
analysis by using Fast Fourier transform (FFT) to iden‑
tify neural signaling and sleep disturbances induced by 
prolonged administration of dexamethasone in rats. 
Microanalysis of EEG signals was performed to detect 




16 adult male Wistar rats (weighing 300‑350 g, n=8 
per group) were obtained from Southern Laboratory 
Animal Facility, Prince of Songkla University, Thailand. 
The rats were maintained at 22°C with a 12/12 dark/
light cycle (light on at 7:00 a.m.). Standard commercial 
food pellets and filtered tap water were available ad 
libitum. The experimental protocols described in this 
study were approved and guided by the Animal Ethics 
Committee of the Prince of Songkla University. 
Surgical procedures were carried out according 
to a previous study (Cheaha et al., 2014). Briefly, an‑
imals were anesthetized with intramuscular injection 
of 60 mg/kg Zoletil® 100 (Virbac, Thailand Co. Ltd.). 
Stainless steel screw electrodes were implanted on the 
skull over the frontal cortex (AP; +3, ML; 3) and the pa‑
rietal cortex (AP; ‑4, ML; 4) on the left side skull. The 
reference and ground electrodes were placed at mid‑
line above the cerebellum. Bipolar wire electrodes 
(PFA‑coated stainless steel wire with coated diameter 
139.7 µm (Cata log No. 79110A‑M system) were insert‑
ed into the dorsal neck muscles for electromyography 
(EMG). All electrodes were secured in place with acrylic 
resin (Unifast Trad, Japan). After surgery, animals were 
individually housed in a single cage and observed for 
approximately 15 days to ensure full recovery. The an‑
tibiotic ampicillin (General Drug House Co., Ltd., Thai‑
land) was applied (80 mg/kg, i.m.) for 4 days to prevent 
infection. Rats were randomly divided as control and 
dexamethasone groups for 21‑day treatment. Control 
rats received 0.9% saline (i.p.) (n=8), whereas treated 
rats received 0.5 mg/kg dexamethasone (i.p.) (n=8). In‑
jection was performed at 9:00 a.m. and EEG recording 
started at 1:00 p.m.
Dexamethasone preparation
Dexon® (General Drugs House co., Ltd.) was diluted 
in 0.9% saline to a final concentration of 0.5 mg/ml. 
Both control and dexamethasone groups were injected 
with a volume of 1 ml/kg. 
EEG recording
The process of recording was performed as previ‑
ously described (Cheaha et al., 2014). EEG signals of in‑
dividual rats in a recording chamber were recorded for 
2‑h period through recording cables. EEG signals were 
amplified with a low‑pass 60 Hz, high‑pass 0.1 s and 
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digitized at 400 Hz by a PowerLab/4SP system (ADIn‑
struments) with 12‑bit A/D, and stored in a PC through 
the LabChart ADInstruments software. The EEG signals 
were processed through 1.25‑45 Hz band pass filter. 
The digitized EEG data were segmented into 1,024 data 
points (50% overlap) and the signals were converted to 
power spectra by the FFT algorithm (Hanning window 
cosine transform). Then, the power spectra of 2.56‑sec 
sweeps of a selected period were averaged to create the 
power spectra of the period. In each power spectrum, 
values were divided into 5 frequency bands: delta, 
1.25‑4.5 Hz; theta, 4.75‑6.75 Hz; alpha, 7‑12.5 Hz; beta, 
12.75‑30 Hz and gamma, 30.25‑45 Hz. EEG powers in 
each frequency band of each group were averaged and 
expressed as power (µV2) and power density (µV2/Hz). 
EEG powers of animals were analyzed from 2‑hr records 
on day 1, 6, 11, 16 and 21 following the start of dexa‑
methasone treatment.
Analysis of sleep‑wake cycle
EEG signals from the frontal and parietal corti‑
ces and EMG signals from the dorsal neck muscles 
were used to determine sleep‑wake states of animals. 
Awake periods (AW) were identified by fast wave, low 
amplitude EEG and the presence of high EMG activity 
(Fig. 1A). The interchange among different sleep‑wake 
periods can be displayed in spectrograms for visual in‑
spection (Fig. 1B). Slow wave sleep (SWS) or non‑rapid 
Fig. 1. Determination of sleep‑wake states from frontal (FC) and parietal (PC) EEG signals. Raw EEG and EMG signals were used to identify awake, slow wave 
sleep (SWS) and (rapid eye movement (REM) sleep periods (A). The spectrograms displaying spectral power are expressed and referenced with color codes 
of frequency (Y axis) in time domain (X axis) (B). Each sleep‑wake state was confirmed with specific characteristic of EEG power densities (C).
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eye movement sleeps (non‑REM sleep) were identified 
with slow wave and high amplitude EEG. REM sleeps 
were detected with fast wave, low amplitude EEG and 
the absence EMG activity. Specific characteristics of the 
EEG power spectrum were examined by using FFT for 
quantitative data (Fig. 1C). Awake signals were identi‑
fied with peaks at theta wave for frontal and parietal 
EEG. On the other hand, SWSs were recognized with 
peaks specifically within delta range for both frontal 
and parietal EEG. The most unique characteristic was 
detected during REM sleep when parietal EEG exhibited 
dominant theta peak whereas frontal EEG had relative‑
ly overall low power.
Data analysis
Power densities (µV2/Hz) of frontal and parietal EEG 
during baseline and post‑treatment period were calcu‑
lated. Baseline values were set to 100% and changes of 
post‑treatment values were documented as percent of 
baseline values. For spindle investigation, frontal EEG 
was scanned through 6‑10 and 10‑14 Hz filters from 
a 2‑hr recording for HVSs and regular sleep spindles, 
respectively. Numbers of occurrences of spindles were 
counted from loops or peaks of EEG power density of 
filtered signal. Therefore, data were normalized and 
expressed as numbers of spindle per hour.
All data were expressed as mean ±S.E.M. Effects of 
treatment were determined by using one‑way ANOVA 
followed by the Student Newman Keuls test for multiple 
comparison. T‑test was used for the analysis of two‑set 
data. *, ** and *** indicate p<0.05, 0.01 and 0.001, re‑
spectively, for statistically significant differences.
RESULTS
Effects of repeated dexamethasone exposures  
on EEG power spectrum 
The broad spectrum of EEG power was divided into 
5 frequency bands: delta, theta, alpha, beta and gam‑
ma. Therefore, values of different time points were 
analyzed for each frequency range. All data were nor‑
malized with baseline values obtained before the start 
of dexamethasone treatment and expressed as percent 
baseline (% baseline). Data were shown in comparison 
to controls. Frontal EEG analysis revealed no significant 
change was induced by the dexamethasone in any dura‑
tion of any frequency band (Fig. 2A). However, the anal‑
ysis of parietal EEG signals indicated that dexametha‑
sone significantly increased powers of slow waves which 
included delta, theta and alpha bands (Fig. 2B). Multiple 
comparisons indicated that significant changes were 
observed only on day 21 for delta band. In theta band, 
significant changes were confirmed as early as day 11 
and until day 21. Alpha powers were also significantly 
increased on day 16 until day 21.
Effects of dexamethasone on sleep‑wake patterns
Sleep‑wake patterns were analyzed from EEG sig‑
nals recorded on day 21 of dexamethasone treatment. 
Hypnograms were created to display dynamic ap‑
pearances of sleep‑wake parameters which included 
awake, slow wave sleep (SWS) and rapid eye move‑
ment (REM) in time domain (Fig. 3A). Time fragments 
of each parameter during a 2‑hr period of recording 
Fig. 2. Effects of repeated dexamethasone treatment on EEG powers in the frontal (A) and parietal (B) cortices. Baseline activities were evaluated from 
2‑hr recordings on the first day before drug administration. After the administration, EEG was recorded for 2 h on each assigned day. EEG power spectra 
were divided into 5 frequency ranges: delta, theta, alpha, beta and gamma. Data are expressed as mean ± S.E.M. of power density (% baseline). *p<0.05, 
**p<0.01, ***p<0.001 compared with control values.
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were summed. Total times spent in awake periods, SWS 
and REM sleep were analyzed and expressed as per‑
cent of total (Fig. 3B). The results showed that chron‑
ic dexamethasone exposure significantly decreased 
the percentage of REM sleep (Dx=1.22±2.04 and con‑
trol=6.42±0.59 (t14=‑6.926, P<0.001)). No change in time 
spent was seen for awake and SWS periods. The analysis 
of sleep latency also revealed no significant change in‑
duced by dexamethasone (Dx=16.17±12.49 min and con‑
trol=36.22±8.31 min (t14=‑3.780, P<0.01)) (Fig. 3C). 
Fig. 3. Effects of repeated dexamethasone exposures on sleep‑wake cycle. Hypnograms of representative rats from control and dexamethasone groups 
were created to show the dynamic presentation of sleep‑wake states (A). Mean of time spent in each brain state and sleep latency are shown (B and C, 
respectively). Sleep‑wake data were analyzed from EEG signals recorded for 2 h on day 21 of the treatment. **p<0.01 compared with control levels.
Fig. 4. Effects of repeated dexamethasone treatment on power of Delta (A), Theta (B), Alpha (C), Beta (D) and Gamma (E) waves. EEG powers of 5 frequency 
waves were analyzed from parietal (PC) EEG and frontal (FC) EEG on day 21 of dexamethasone treatment. Data were taken from 5‑min continuous periods 
of awake and slow wave sleep (SWS) brain states for separate analysis. 
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Effects of repeated dexamethasone treatment  
on EEG powers during awake and slow wave 
sleep periods
EEG powers were separately analyzed with regard 
to specific awake and SWS periods. Signals were taken 
from the first 5‑min recording of the first appearance 
of awake or SWS periods after dexamethasone treat‑
ment for 21 days. EEG power analysis was performed 
for 5 frequency ranges. Awake EEG analysis confirmed 
that dexamethasone significantly induced increases in 
power of slow frequency bands which included delta, 
theta and alpha activity for parietal EEG (Fig. 4A) and 
only alpha activity for frontal EEG (Fig. 4C). However, 
the analysis of EEG signals during SWS revealed the only 
significant change seen was within beta band for both 
parietal and frontal EEG (Fig. 4B and 4D, respectively). 
Effects of repeated dexamethasone treatment  
on EEG spindles
The distribution of spindles was determined from 
raw EEG signals. Types of EEG spindles were character‑
ized by power spectrum analysis of frontal EEG signals 
using FFT. Raw EEG signals were filtered for 6‑10 and 
10‑14 Hz oscillations to extract EEG spindles and in‑
spect their features. Two main types of spindles were 
characterized. Sleep spindles were recognized from 
frontal EEG with relatively low power when filtered for 
10‑14 Hz activity (Fig. 5A). When filtered for 6‑10 Hz ac‑
tivity, HVSs were detected. They exhibited high ampli‑
tude loops with peak frequency in the range. Therefore, 
numbers of both types of EEG spindle were counted 
from a 2‑hr period of EEG recordings after dexameth‑
asone treatment for 21 days. The results showed that 
Fig. 5. Effects of repeated dexamethasone treatment on sleep‑wake cycle. Identification of normal sleep spindles and high‑voltage spindles (HVSs) was 
performed by using EEG signals recorded on day 21 of dexamethasone treatment (A). EEG signals were filtered and EEG spindles were identified from 
power density of frontal EEG signals. There are 2 types of EEG spindle according to their features and EEG power densities: regular sleep spindle (10‑14 Hz) 
and HVS (6‑10 Hz). Numbers of spindles during slow wave sleep (SWS) and awake (AW) periods were analyzed (B). Data are expressed as mean ± S.E.M. 
number of spindle (times/h). *p<0.05, **p<0.01 compared with control levels.
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repeated exposure to dexamethasone had no effect on 
normal sleep spindles analyzed during SWS brain state 
(Fig. 5B). However, it was found to significantly increase 
the number of HVSs per hour both during awake and 
SWS states (AW: Dx=1.94±0.36 and control=0.82±0.25 
(t14=7.228, P<0.001) and SWS: Dx=5.13±0.62 and con‑
trol=1.44±0.36 (t14=14.558, P<0.001)). 
Correlations between HVSs and EEG power 
Regression analyses between type of spindle and 
EEG power of each band of frequency waves were per‑
formed. No significant correlation was seen for the nor‑
mal sleep spindle (data not shown). In contrast, posi‑
tive correlations were found between number of HVSs 
and EEG powers. During the awake period, the number 
of HVSs was positively correlated with only Theta pow‑
er (Fig. 6A). Relatively greater relationships were seen 
during the SWS period. Significant correlations be‑
tween numbers of HVSs and EEG power of delta, theta 
and alpha waves were found (Fig. 6B‑D, respectively). 
The distributions of slow frequency powers against 
numbers of HVSs completely distinguished between 
the values of control and dexamethasone groups.
DISCUSSION 
The present findings have demonstrated that analy‑
sis of EEG spectral powers and sleep components yield‑
ed differential parameters for control and dexametha‑
sone‑treated rats. Longitudinal study of EEG also allowed 
for the detection of changes in slow wave as early as day 
11 of dexamethasone treatment. These parameters may 
be of particular significance for EEG studies when re‑
peated measures are possible and convenient. The sup‑
pression of REM sleep and the detection of HVSs induced 
Fig. 6. Linear regression analyses of relationships between EEG power and number of high‑voltage spindles (HVSs) during awake and slow wave sleep 
brain states. Relationships between Theta and HVS during awake (A), Delta and HVS during SWS (B), Theta and HVS during SWS (C) and Alpha and HVS 
during SWS were analyzed from EEG signals of control and dexamethasone‑treated rats. Correlations are expressed as R‑square (R2) and linear equation 
and statistically confirmed with p values.
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by long‑term treatment with dexamethasone also clear‑
ly distinguished electrical brain signals between groups. 
Dexamethasone is a synthetic steroid with high 
glucocorticoid activity. It is widely used due to its an‑
ti‑inflammatory effects (Leggas et al., 2009; Choksi et 
al., 2013). However, its use has been linked with mecha‑
nisms that increase oxidative stress through long‑last‑
ing upregulation of reactive oxygen species (Schafer et 
al., 2005; Kraaij et al., 2011). Down‑regulation of genes 
involved in the mitochondrial respiratory chain and 
those that encode antioxidant enzymes were induced 
by dexamethasone (Mutsaers and Tofighi, 2012). There‑
fore, oxidative stress induced by dexamethasone has 
been extensively used as a model for evaluation of pro‑
tective effects of novel therapeutic substances (Hu et 
al., 2009; Gao et al., 2010). 
Increases in slow wave activity have been typical 
findings in neurodegenerative disease (Coben et al., 
1983; Kwak, 2006). Global cortical dysfunction was also 
found to be associated with increased theta activity in 
EEG spectra and a significant increase in delta power was 
observed in later stages of deterioration in Alzheimer’s 
disease (Prichep et al., 1994; Helkala et al., 1996). Neuro‑
nal loss is proposed to underlie the increased slow wave 
oscillation. In urethane‑anesthetized rats, high doses 
of cholinergic agonist or cholinesterase inhibitor were 
demonstrated to decrease slow wave activity including 
low frequency power (Toth et al., 2012). Basically, acetyl‑
choline is primarily synthesized in the nucleus basalis of 
Meynert and basal forebrain and are the major sources 
of cholinergic afferents terminating in many brain re‑
gions, including the areas involved in learning and mem‑
ory processes and the neocortex, that would impact neo‑
cortical EEG as well as sleep‑wake stages (Selden et al., 
1998; Semba, 2000). Moreover, increased delta and theta 
amplitudes in rats were induced by lesioning of the nu‑
cleus basalis and, therefore, reversed by anticholinester‑
ase and pilocarpine (Riekkinen Jr. et al., 1991). Elevat‑
ed acetylcholine release is associated with low‑voltage 
fast oscillation during wakefulness and REM sleep, while 
a reduction in its release is found during SWS when Delta 
waves dominate the EEG (Kanai and Szerb, 1965; Celesia 
and Jasper, 1966). Degeneration of cholinergic basal fore‑
brain has been commonly found in Alzheimer’s diseases 
(Grothe et al., 2014). Moreover, monoamines also have 
a role in these actions as combined cholinergic‑mono‑
aminergic stimulation resulted in stronger effects in re‑
versing learning impairments and EEG slowing than cho‑
linergic enhancement alone in a rat model (Dringenberg, 
2000). EEG analysis in Alzheimer’s patients also revealed 
slowed mean frequency activity and reduced interplay 
among cortical regions (Jeong, 2004). Previously, a loss 
of neurons and glial cells in regions of the hippocam‑
pus was observed following long‑term dexamethasone 
treatment (Issuriya et al., 2014). These consistent re‑
ports suggest possible links between elevated slow wave 
EEG power and degeneration of neuronal substrates that 
may also underlie neuropathology induced by long‑term 
dexamethasone treatment.
In addition to EEG abnormalities, sleep disturbances 
have also been widely reported in cases of neurodegen‑
erative diseases (Gagnon et al., 2002; Jackson and Sny‑
der, 2008). Mostly, sleep disruption is detected before 
the onset of relevant neuropsychological impairments 
(Tranah et al., 2011; Ju et al., 2013). In Alzheimer’s dis‑
ease, sleep disturbances are positively correlated with 
amyloid deposition (Ju et al., 2013). In particular, REM 
sleep deprivation was hypothesized to be linked with 
an impairment in learning recent information (Chris‑
tos, 1993). A decrease in REM sleep was among chang‑
es in parameters found in mild cognitive impairment 
subjects and to a greater extent in Alzheimer’s patients 
(Maestri et al., 2015). In animal models of Alzheimer’s 
disease, a reduction of REM and changes in EEG spectra 
were observed earlier than the occurrence of behavior‑
al changes (Schneider et al., 2014). It was hypothesized 
that loss of REM in patients and mouse models is asso‑
ciated with a decrease in cholinergic tone and donepe‑
zil, a cholinesterase inhibitor, was demonstrated to re‑
store some normal sleep in animals (Wisor et al., 2005) 
and Alzheimer’s patients (Mizuno et al., 2004).
The present study analyzed features of spindles. 
6‑10 Hz and 10‑14 Hz EEG oscillations were specifically 
investigated. Significant increases were observed for 
6‑10 Hz but not 10‑14 Hz activity. Previously, sleep spin‑
dles relatively similar to 6‑10 Hz EEG oscillation have 
been characterized in rats (Marini et al., 2008). This 
type of electrical activity, known as HVSs, was seen in 
rats with dopamine depletion (Ge et al., 2012) or sys‑
temic blockade of dopamine D2‑like receptor (Yang et 
al., 2013). In a rat model of Parkinson’s disease induced 
by 6‑hydroxydopamine lesioning, high frequency stim‑
ulation of the sub‑thalamic nucleus, a brain region in‑
volved in the cortical‑basal ganglia loop, was found to 
restore the HVSs and motor deficits to normal states 
(Yang et al., 2015).
In terms of mechanisms, long‑term treatment of 
dexamethasone might be proposed to affect at least 
cholinergic and dopaminergic groups of neurons in 
the brain. Glucocorticoid receptors are present on do‑
paminergic cells (Harfstrand et al., 1986) and found 
to mediate several essential processes of cholinergic 
neurons in the brain (Guijarro et al., 2006). Prolonged 
dexamethasone administration likely leads to hyperac‑
tivation of these neuronal cells through glucocorticoid 
receptors, ultimately causing cell death and neurode‑
generative symptoms that might mimic those induced 
by oxidative stress.
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Finally, the present study pointed out several cor‑
relations between EEG powers and HVSs in a rat model. 
These findings highlighted several indicative parame‑
ters of neuropathology for possible application at the 
clinical level. Through longitudinal monitoring of EEG 
signals, the analysis of slow frequency could allow for 
early detection of neuropathologies. Though the reduc‑
tion of REM sleep was also an obvious and consistent 
parameter in previous reports, it only became evident 
relatively late when most of the symptoms had already 
emerged. Additionally, it is of particularly interest that 
the excessive appearance of HVSs especially during SWS 
was strongly correlated with increased theta oscillation. 
CONCLUSIONS 
Taken together, the present data demonstrated that 
changes in slow frequency oscillation appeared to be sensi‑
tive to prolonged dexamethasone treatment. REM suppres‑
sion and HVSs also emerged at later stages. These findings 
clearly confirmed that long‑term exposure to the cortico‑
steroid led to changes in electrical brain activity. Moreover, 
this animal model may be useful for testing novel neurode‑
generative disease‑modifying drugs or substances. 
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